Your browser is no longer supported. Please, upgrade your browser.
ProQR Therapeutics N.V.
Index- P/E- EPS (ttm)-1.29 Insider Own2.95% Shs Outstand50.14M Perf Week20.04%
Market Cap277.64M Forward P/E- EPS next Y-1.27 Insider Trans0.00% Shs Float44.73M Perf Month23.34%
Income-63.10M PEG- EPS next Q-0.30 Inst Own69.30% Short Float1.35% Perf Quarter33.42%
Sales11.70M P/S23.73 EPS this Y-27.00% Inst Trans0.01% Short Ratio1.48 Perf Half Y5.69%
Book/sh1.66 P/B3.25 EPS next Y-18.70% ROA-48.80% Target Price- Perf Year-34.51%
Cash/sh2.10 P/C2.57 EPS next 5Y- ROE-63.90% 52W Range3.40 - 9.43 Perf YTD28.33%
Dividend- P/FCF- EPS past 5Y-21.50% ROI-53.40% 52W High-42.84% Beta0.52
Dividend %- Quick Ratio8.50 Sales past 5Y43.90% Gross Margin- 52W Low58.53% ATR0.43
Employees154 Current Ratio8.50 Sales Q/Q-40.00% Oper. Margin- RSI (14)68.15 Volatility14.92% 9.15%
OptionableYes Debt/Eq0.49 EPS Q/Q15.70% Profit Margin- Rel Volume9.09 Prev Close5.27
ShortableYes LT Debt/Eq0.46 Earnings- Payout- Avg Volume407.15K Price5.39
Recom1.70 SMA2022.46% SMA5028.44% SMA2009.64% Volume3,701,492 Change2.28%
Nov-03-20Resumed Cantor Fitzgerald Overweight $22
Mar-12-19Reiterated Chardan Capital Markets Buy $21 → $25
Dec-19-18Initiated RBC Capital Mkts Outperform
Nov-15-18Initiated Citigroup Buy $32
Sep-19-18Initiated Evercore ISI Outperform
Sep-26-17Reiterated JMP Securities Mkt Outperform $14 → $20
Jun-20-16Initiated Chardan Capital Markets Neutral $4.50
Oct-15-14Initiated Deutsche Bank Buy $32
Oct-13-14Initiated H.C. Wainwright Buy $40
Jan-21-21 10:34AM  
Jan-18-21 06:37AM  
Jan-07-21 07:00AM  
Dec-18-20 07:00AM  
Nov-30-20 09:32PM  
Nov-18-20 07:00AM  
Nov-17-20 08:21AM  
Nov-16-20 08:35AM  
Nov-02-20 07:00AM  
Oct-05-20 07:00AM  
Sep-24-20 04:10PM  
Sep-21-20 03:23PM  
Sep-03-20 07:00AM  
Aug-06-20 04:30PM  
Jul-23-20 09:21AM  
Jul-21-20 07:00AM  
Jul-14-20 04:30PM  
Jul-13-20 04:30PM  
Jun-29-20 08:32AM  
Jun-23-20 11:32AM  
Jun-22-20 02:42PM  
Jun-15-20 10:00AM  
Jun-12-20 07:00AM  
Jun-08-20 07:00AM  
May-29-20 08:55AM  
May-25-20 07:00AM  
May-07-20 08:55AM  
Apr-28-20 08:47AM  
Mar-31-20 06:00AM  
Mar-25-20 04:15PM  
Mar-05-20 08:29AM  
Feb-28-20 11:23AM  
Feb-26-20 07:00AM  
Feb-24-20 07:00AM  
Feb-06-20 07:00AM  
Jan-30-20 07:00AM  
Jan-21-20 04:09AM  
Jan-06-20 09:45AM  
Dec-23-19 11:51AM  
Dec-17-19 05:20PM  
Dec-12-19 03:19PM  
Dec-11-19 02:42PM  
Nov-21-19 08:25AM  
Nov-18-19 07:23AM  
Nov-13-19 07:00AM  
Nov-06-19 06:09PM  
Nov-05-19 11:45AM  
Oct-24-19 12:50PM  
Oct-23-19 07:42AM  
Oct-18-19 08:20AM  
Oct-16-19 07:06AM  
Oct-15-19 11:17PM  
Oct-10-19 07:31AM  
Oct-07-19 07:00AM  
Oct-01-19 09:09AM  
Sep-30-19 07:00AM  
Sep-24-19 10:33AM  
Sep-13-19 11:08AM  
Sep-09-19 07:00AM  
Aug-14-19 12:18PM  
Aug-13-19 11:53AM  
Aug-12-19 07:00AM  
Aug-07-19 10:05AM  
Jul-29-19 07:00AM  
Jul-26-19 01:31PM  
Jul-02-19 07:00AM  
Jun-29-19 05:34PM  
Jun-03-19 07:00AM  
May-27-19 10:56AM  
May-15-19 07:00AM  
May-08-19 02:29PM  
Apr-22-19 07:00AM  
Apr-18-19 07:00AM  
Apr-16-19 07:26PM  
Apr-15-19 07:00AM  
Apr-01-19 07:00AM  
Mar-26-19 04:01PM  
Mar-11-19 08:00AM  
Mar-05-19 07:00AM  
Feb-28-19 09:50AM  
Feb-27-19 07:00AM  
Feb-21-19 09:34AM  
Jan-29-19 10:11AM  
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.